SCYNEXIS to Participate in Upcoming Investor Conferences

Rhea-AI Summary

SCYNEXIS (Nasdaq: SCYX), a clinical-stage biotechnology company, announced participation in two upcoming investor conferences in New York City. The company will join a fireside chat at the 12th Cantor Global Healthcare Conference on Friday, September 11, 2026, at 9:45 a.m. ET, which will be webcast live with a replay available for 90 days. SCYNEXIS will also take part in 1x1 investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference from September 14–16, 2026.

News Market Reaction – SCYX

-1.15%

-1.15% Session close to close

In the Sep 1 session, SCYX declined 1.15%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

JERSEY CITY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced that the company will participate in the following investor conferences:

• 12th Cantor Global Healthcare Conference in New York City
  Fireside chat: Friday, September 11, 2026, at 9:45 a.m. ET.

• H.C. Wainwright 28th Annual Global Investment Conference in New York City
  1x1 investor meetings: September 14-16, 2026

A live webcast of the Cantor fireside chat will be available here. A replay will be available for 90 days following the event.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development. For more information, visit www.scynexis.com

CONTACT:
Investor Relations
John Fraunces
LifeSci Advisors
Tel: 917-355-2395
jfraunces@lifesciadvisors.com

FAQ

When will SCYNEXIS (SCYX) present at the 12th Cantor Global Healthcare Conference in 2026?

SCYNEXIS will participate in a fireside chat on Friday, September 11, 2026, at 9:45 a.m. ET. According to SCYNEXIS, this session is part of the 12th Cantor Global Healthcare Conference in New York City.

How can investors access the SCYNEXIS (SCYX) Cantor conference fireside chat webcast?

Investors can watch a live webcast of the SCYNEXIS fireside chat at the Cantor conference online. According to SCYNEXIS, a replay of the webcast will remain available for 90 days following the event.

What are the dates of SCYNEXIS (SCYX) 1x1 investor meetings at the H.C. Wainwright 2026 conference?

SCYNEXIS will hold 1x1 investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference from September 14–16, 2026. According to SCYNEXIS, these meetings will take place in New York City.

What type of company is SCYNEXIS (SCYX) participating in these 2026 investor conferences?

SCYNEXIS is a clinical-stage biotechnology company focused on therapies for severe and difficult-to-treat diseases. According to SCYNEXIS, it is developing innovative treatments for conditions with significant unmet medical need.